Search

Your search keyword '"Rossella Ribolla"' showing total 2 results
Start Over Author "Rossella Ribolla" Publisher nature publishing group
2 results on '"Rossella Ribolla"'

1. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

Author

Stefania Oliva, Davine Hofste op Bruinink, Lucie Rihova, Mattia D’Agostino, Lucia Pantani, Andrea Capra, Bronno van der Holt, Rossella Troia, Maria Teresa Petrucci, Tania Villanova, Pavla Vsianska, Romana Jugooa, Claudia Brandt-Hagens, Milena Gilestro, Massimo Offidani, Rossella Ribolla, Monica Galli, Roman Hajek, Francesca Gay, Michele Cavo, Paola Omedé, Vincent H. J. van der Velden, Mario Boccadoro, and Pieter Sonneveld

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted an MRD correlative study of the EMN02/HO95 MM phase III trial in newly diagnosed MM patients achieving a suspected complete response before maintenance and every 6 months during maintenance. Patients received high-dose melphalan (HDM) versus bortezomib-melphalan-prednisone (VMP) intensification, followed by bortezomib-lenalidomide-dexamethasone (VRd) versus no consolidation, and lenalidomide maintenance. Bone marrow (BM) samples were processed in three European laboratories, applying EuroFlow-based MFC protocols (eight colors, two tubes) with 10−4−10−5 sensitivity. At enrollment in the MRD correlative study, 76% (244/321) of patients were MRD-negative. In the intention-to-treat analysis, after a median follow-up of 75 months, 5-year progression-free survival was 66% in MRD-negative versus 31% in MRD-positive patients (HR 0.39; p

Published
2021
Full Text
View/download PDF

2. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

Author

Claudia Brandt-Hagens, Stefania Oliva, Pavla Všianská, Maria Teresa Petrucci, Roman Hájek, Romana Jugooa, Monica Galli, Mattia D'Agostino, Rossella Ribolla, Davine Hofste op Bruinink, Pieter Sonneveld, Andrea Capra, Bronno van der Holt, Tania Villanova, Massimo Offidani, Michele Cavo, Lucia Pantani, Rossella Troia, Mario Boccadoro, Paola Omedè, Lucie Rihova, Milena Gilestro, Vincent H.J. van der Velden, Oliva S., Bruinink D.H., Rihova L., D'Agostino M., Pantani L., Capra A., van der Holt B., Troia R., Petrucci M.T., Villanova T., Vsianska P., Jugooa R., Brandt-Hagens C., Gilestro M., Offidani M., Ribolla R., Galli M., Hajek R., Gay F., Cavo M., Omede P., van der Velden V.H.J., Boccadoro M., Sonneveld P., Hematology, and Immunology

Subjects
Melphalan, Male, medicine.medical_specialty, Neoplasm, Residual, Population, Urology, Bone Marrow Cells, Article, Dexamethasone, Disease-Free Survival, Bortezomib, EuroFlow, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Autograft, Humans, Medicine, Autografts, education, Lenalidomide, Multiple myeloma, RC254-282, education.field_of_study, Antineoplastic Combined Chemotherapy Protocol, medicine.diagnostic_test, business.industry, Hematopoietic Stem Cell Transplantation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Hematology, Translational research, Middle Aged, medicine.disease, Flow Cytometry, Minimal residual disease, body regions, Survival Rate, medicine.anatomical_structure, Risk factors, Oncology, Bone Marrow Cell, Female, Bone marrow, business, Multiple Myeloma, medicine.drug, Fluorescence in situ hybridization, Human
Abstract

Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) is the most effective tool to define a deep response in multiple myeloma (MM). We conducted an MRD correlative study of the EMN02/HO95 MM phase III trial in newly diagnosed MM patients achieving a suspected complete response before maintenance and every 6 months during maintenance. Patients received high-dose melphalan (HDM) versus bortezomib-melphalan-prednisone (VMP) intensification, followed by bortezomib-lenalidomide-dexamethasone (VRd) versus no consolidation, and lenalidomide maintenance. Bone marrow (BM) samples were processed in three European laboratories, applying EuroFlow-based MFC protocols (eight colors, two tubes) with 10−4−10−5 sensitivity. At enrollment in the MRD correlative study, 76% (244/321) of patients were MRD-negative. In the intention-to-treat analysis, after a median follow-up of 75 months, 5-year progression-free survival was 66% in MRD-negative versus 31% in MRD-positive patients (HR 0.39; p p

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results